{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T13:55:13Z","timestamp":1713794113655},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,27]]},"DOI":"10.7759\/cureus.30742","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T08:08:51Z","timestamp":1666858131000},"source":"Crossref","is-referenced-by-count":1,"title":["Comparison of Interrupted and Uninterrupted Anticoagulation Therapy for Patients With Atrial Fibrillation Undergoing Catheter Ablation: A Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Sidra","family":"Jamil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saima","family":"Batool","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad","family":"Ehsan Ullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yared N","family":"Aschalew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tafseer","family":"Zahra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leladher","family":"Maheshwari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Venkata","family":"Anirudh Chunchu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adil","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study","volume":"129","author":"Chugh SS","year":"2014","unstructured":"Chugh SS, Havmoeller R, Narayanan K, et al.. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014, 129:837-47. 10.1161\/CIRCULATIONAHA.113.005119","journal-title":"Circulation"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7326\/M13-1467","article-title":"Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review","volume":"160","author":"Al-Khatib SM","year":"2014","unstructured":"Al-Khatib SM, Allen LaPointe NM, Chatterjee R, et al.. Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med. 2014, 160:760-73. 10.7326\/M13-1467","journal-title":"Ann Intern Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.36660\/abc.20200110","article-title":"Uninterrupted direct oral anticoagulants in atrial fibrillation catheter ablation: ready for prime time","volume":"114","author":"Cardoso R","year":"2020","unstructured":"Cardoso R, D'Avila A. Uninterrupted direct oral anticoagulants in atrial fibrillation catheter ablation: ready for prime time. Arq Bras Cardiol. 2020, 114:443-5. 10.36660\/abc.20200110","journal-title":"Arq Bras Cardiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS):  The task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks G","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, et al.. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS):  The task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021, 42:373-498. 10.1093\/eurheartj\/ehaa612","journal-title":"Eur Heart J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.113.000768","article-title":"Complications of catheter ablation of atrial fibrillation: a systematic review","volume":"6","author":"Gupta A","year":"2013","unstructured":"Gupta A, Perera T, Ganesan A, et al.. Complications of catheter ablation of atrial fibrillation: a systematic review. Circ Arrhythm Electrophysiol. 2013, 6:1082-8. 10.1161\/CIRCEP.113.000768","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euu007","article-title":"Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation","volume":"16","author":"Provid\u00eancia R","year":"2014","unstructured":"Provid\u00eancia R, Marijon E, Albenque JP, et al.. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation. Europace. 2014, 16:1137-44. 10.1093\/europace\/euu007","journal-title":"Europace"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.113.000320","article-title":"Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation","volume":"6","author":"Bassiouny M","year":"2013","unstructured":"Bassiouny M, Saliba W, Rickard J, et al.. Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol. 2013, 6:460-6. 10.1161\/CIRCEP.113.000320","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2017.09.015","article-title":"Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: analysis of the BRIDGE trial","volume":"195","author":"Clark NP","year":"2018","unstructured":"Clark NP, Douketis JD, Hasselblad V, Schulman S, Kindzelski AL, Ortel TL. Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: analysis of the BRIDGE trial. Am Heart J. 2018, 195:108-14. 10.1016\/j.ahj.2017.09.015","journal-title":"Am Heart J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2016.04.027","article-title":"Periprocedural management of novel oral anticoagulants during atrial fibrillation ablation: controversies and review of the current evidence","volume":"25","author":"Abed HS","year":"2016","unstructured":"Abed HS, Chen V, Kilborn MJ, Sy RW. Periprocedural management of novel oral anticoagulants during atrial fibrillation ablation: controversies and review of the current evidence. Heart Lung Circ. 2016, 25:1164-76. 10.1016\/j.hlc.2016.04.027","journal-title":"Heart Lung Circ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013504.pub2","article-title":"Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias","volume":"10","author":"Bawazeer GA","year":"2021","unstructured":"Bawazeer GA, Alkofide HA, Alsharafi AA, et al.. Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias. Cochrane Database Syst Rev. 2021, 10:CD013504. 10.1002\/14651858.CD013504.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2016.09.011","article-title":"Trends in transesophageal echocardiography use, findings, and clinical outcomes in the era of minimally interrupted anticoagulation for atrial fibrillation ablation","volume":"3","author":"Balouch M","year":"2017","unstructured":"Balouch M, Gucuk Ipek E, Chrispin J, et al.. Trends in transesophageal echocardiography use, findings, and clinical outcomes in the era of minimally interrupted anticoagulation for atrial fibrillation ablation. JACC Clin Electrophysiol. 2017, 3:329-36. 10.1016\/j.jacep.2016.09.011","journal-title":"JACC Clin Electrophysiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.11.024","article-title":"2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American College of Cardiology Clinical Expert Consensus Document Task Force","volume":"69","author":"Doherty JU","year":"2017","unstructured":"Doherty JU, Gluckman TJ, Hucker WJ, Januzzi JL Jr, Ortel TL, Saxonhouse SJ, Spinler SA. 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American College of Cardiology Clinical Expert Consensus Document Task Force. J Am Coll Cardiol. 2017, 69:871-98. 10.1016\/j.jacc.2016.11.024","journal-title":"J Am Coll Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00380-019-01370-9","article-title":"Differences in prothrombotic response between the uninterrupted and interrupted apixaban therapies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: a randomized controlled study","volume":"34","author":"Ando M","year":"2019","unstructured":"Ando M, Inden Y, Yoshida Y, et al.. Differences in prothrombotic response between the uninterrupted and interrupted apixaban therapies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: a randomized controlled study. Heart Vessels. 2019, 34:1533-41. 10.1007\/s00380-019-01370-9","journal-title":"Heart Vessels"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.006426","article-title":"Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial","volume":"129","author":"Di Biase L","year":"2014","unstructured":"Di Biase L, Burkhardt JD, Santangeli P, et al.. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial. Circulation. 2014, 129:2638-44. 10.1161\/CIRCULATIONAHA.113.006426","journal-title":"Circulation"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euy224","article-title":"Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy","volume":"21","author":"Nagao T","year":"2019","unstructured":"Nagao T, Suzuki H, Matsunaga S, et al.. Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace. 2019, 21:590-7. 10.1093\/europace\/euy224","journal-title":"Europace"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euy148","article-title":"Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events","volume":"21","author":"Nakamura K","year":"2019","unstructured":"Nakamura K, Naito S, Sasaki T, et al.. Uninterrupted vs. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. Europace. 2019, 21:259-67. 10.1093\/europace\/euy148","journal-title":"Europace"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.1994","article-title":"Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial","volume":"2","author":"Nogami A","year":"2019","unstructured":"Nogami A, Harada T, Sekiguchi Y, et al.. Safety and efficacy of minimally interrupted dabigatran vs uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. JAMA Netw Open. 2019, 2:e191994. 10.1001\/jamanetworkopen.2019.1994","journal-title":"JAMA Netw Open"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2017.11.005","article-title":"A prospective randomized trial of\u00a0apixaban dosing during atrial\u00a0fibrillation\u00a0ablation: the\u00a0AEIOU trial","volume":"4","author":"Reynolds MR","year":"2018","unstructured":"Reynolds MR, Allison JS, Natale A, et al.. A prospective randomized trial of\u00a0apixaban dosing during atrial\u00a0fibrillation\u00a0ablation: the\u00a0AEIOU trial. JACC Clin Electrophysiol. 2018, 4:580-8. 10.1016\/j.jacep.2017.11.005","journal-title":"JACC Clin Electrophysiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2016.03.014","article-title":"Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation","volume":"69","author":"Yoshimura A","year":"2017","unstructured":"Yoshimura A, Iriki Y, Ichiki H, et al.. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. J Cardiol. 2017, 69:228-35. 10.1016\/j.jjcc.2016.03.014","journal-title":"J Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy870","article-title":"When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study","volume":"40","author":"Yu HT","year":"2019","unstructured":"Yu HT, Shim J, Park J, et al.. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. Eur Heart J. 2019, 40:1531-7. 10.1093\/eurheartj\/ehy870","journal-title":"Eur Heart J"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9103073","article-title":"Uninterrupted or minimally interrupted direct oral anticoagulant therapy is a safe alternative to vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation: an updated meta-analysis","volume":"9","author":"Ott\u00f3ffy M","year":"2020","unstructured":"Ott\u00f3ffy M, M\u00e1trai P, Farkas N, et al.. Uninterrupted or minimally interrupted direct oral anticoagulant therapy is a safe alternative to vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation: an updated meta-analysis. J Clin Med. 2020, 9:3073. 10.3390\/jcm9103073","journal-title":"J Clin Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s10840-020-00754-6","article-title":"Meta-analysis of the safety and efficacy of using minimally interrupted novel oral anticoagulants in patients undergoing catheter ablation for atrial fibrillation","volume":"60","author":"Mao YJ","year":"2021","unstructured":"Mao YJ, Wang H, Huang PF. Meta-analysis of the safety and efficacy of using minimally interrupted novel oral anticoagulants in patients undergoing catheter ablation for atrial fibrillation. J Interv Card Electrophysiol. 2021, 60:407-17. 10.1007\/s10840-020-00754-6","journal-title":"J Interv Card Electrophysiol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euw127","article-title":"Perioperative management of antithrombotic treatment during implantation or revision of cardiac implantable electronic devices: the European Snapshot Survey on Procedural Routines for Electronic Device Implantation (ESS-PREDI)","volume":"18","author":"Deharo JC","year":"2016","unstructured":"Deharo JC, Sciaraffia E, Leclercq C, et al.. Perioperative management of antithrombotic treatment during implantation or revision of cardiac implantable electronic devices: the European Snapshot Survey on Procedural Routines for Electronic Device Implantation (ESS-PREDI). Europace. 2016, 18:778-84. 10.1093\/europace\/euw127","journal-title":"Europace"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1592\/phco.31.12.1208","article-title":"Striking a balance between the risks and benefits of anticoagulation bridge therapy in patients with atrial fibrillation: clinical updates and remaining controversies","volume":"31","author":"Garwood CL","year":"2011","unstructured":"Garwood CL, Hwang JM, Moser LR. Striking a balance between the risks and benefits of anticoagulation bridge therapy in patients with atrial fibrillation: clinical updates and remaining controversies. Pharmacotherapy. 2011, 31:1208-20. 10.1592\/phco.31.12.1208","journal-title":"Pharmacotherapy"},{"key":"ref25","article-title":"Risk of pocket hematoma in patients on chronic anticoagulation with warfarin undergoing electrophysiological device implantation: a comparison of different peri-operative management strategies","volume":"19","author":"Proietti R","year":"2015","unstructured":"Proietti R, Porto I, Levi M, et al.. Risk of pocket hematoma in patients on chronic anticoagulation with warfarin undergoing electrophysiological device implantation: a comparison of different peri-operative management strategies. Eur Rev Med Pharmacol Sci. 2015, 19:1461-79.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv177","article-title":"Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation","volume":"36","author":"Cappato R","year":"2015","unstructured":"Cappato R, Marchlinski FE, Hohnloser SH, et al.. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J. 2015, 36:1805-11. 10.1093\/eurheartj\/ehv177","journal-title":"Eur Heart J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/120675-comparison-of-interrupted-and-uninterrupted-anticoagulation-therapy-for-patients-with-atrial-fibrillation-undergoing-catheter-ablation-a-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:43:04Z","timestamp":1707507784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/120675-comparison-of-interrupted-and-uninterrupted-anticoagulation-therapy-for-patients-with-atrial-fibrillation-undergoing-catheter-ablation-a-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,27]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.30742","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,27]]}}}